InfuSystem Secures CMS Approval for Non-Opioid Payment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy INFU?
Source: Businesswire
- Payment Policy Expansion: CMS has added InfuSystem's CADD-Solis™ and Sapphire™ pumps to the list of qualifying products under the NOPAIN Act, allowing separate payments for related surgeries starting January 1, 2026, which is expected to significantly enhance the company's market share in pain management services.
- Growth Potential: This policy change could act as a catalyst for driving volume growth in InfuSystem's pain management business by encouraging healthcare providers to include its services in their formularies, thereby increasing customer acceptance and utilization rates.
- Competitive Advantage: By offering non-opioid treatment options, InfuSystem not only meets patient demands for safer pain management but also strengthens its competitive position in the increasingly regulated healthcare environment, further solidifying its leadership in the medical device sector.
- Long-term Strategic Planning: InfuSystem will continue to collaborate with healthcare providers and device manufacturers to advocate for the adoption of non-opioid treatments, with expectations that this strategy will yield sustained revenue growth and market expansion opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INFU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INFU
Wall Street analysts forecast INFU stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.600
Low
12.00
Averages
13.67
High
15.00
Current: 9.600
Low
12.00
Averages
13.67
High
15.00
About INFU
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InfuSystem Holdings Reports Strong Q4 2025 Earnings with Strategic Growth Outlook
- Significant Revenue Growth: InfuSystem reported net revenue of $36.2 million for Q4 2025, reflecting a 7% year-over-year increase, with Oncology and Wound Care segments growing by 2.8% and over 160% respectively, indicating strong performance in the medical device market.
- Record Adjusted EBITDA: The adjusted EBITDA for Q4 reached $8.8 million, representing 24.3% of net revenue, marking a quarterly record that highlights the company's success in cost control and operational efficiency.
- Optimistic Future Outlook: Management anticipates revenue growth between 6% and 8% for 2026, despite a $7.1 million revenue reduction due to contract restructuring, with new products and technology-driven efficiencies expected to support this growth.
- Robust Cash Flow: Operating cash flow for 2025 exceeded $24.4 million, with available liquidity nearing $58 million at year-end, demonstrating the company's ongoing commitment to capital allocation and shareholder value creation.
See More
InfuSystem Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: InfuSystem reported Q4 GAAP EPS of $0.10, beating expectations by $0.03, indicating robust profitability, while revenue reached $36.2 million, a 6.9% year-over-year increase, although it fell short of market expectations, reflecting intensified competition.
- Patient Services Growth: Patient Services net revenue was $21.9 million, up 5% year-over-year, indicating sustained growth in this segment, despite overall revenue not fully meeting market forecasts.
- Device Solutions Performance: Device Solutions net revenue reached $14.4 million, a 10% increase year-over-year, showcasing strong performance in equipment sales and further solidifying the company's market position.
- Future Outlook: The company anticipates a $7.1 million, or 5.5%, reduction in net revenue for 2026 due to biomedical services contract restructuring, but expects pro-forma net revenue growth for unaffected business to be between 6% and 8%, demonstrating confidence in future growth.
See More
InfuSystem Reports Record Revenues and Earnings for 2025
- Significant Revenue Growth: InfuSystem achieved net revenues of $143.4 million in 2025, a 6% increase year-over-year, marking the seventh consecutive year of record revenues, demonstrating the company's strong performance and growth potential in the healthcare equipment services market.
- Substantial Net Income Increase: The net income for 2025 reached $6.6 million, up 183% from the previous year, reflecting significant improvements in cost control and operational efficiency, which enhances investor confidence in future profitability.
- Record Adjusted EBITDA: The adjusted EBITDA for 2025 was $31.5 million, a 24% increase, indicating ongoing optimization in profitability and cash flow management, which supports future strategic investments and expansions.
- Robust Cash Flow: Operating cash flow for 2025 was $24.4 million, a 19% increase, providing ample liquidity to support business development and shareholder return plans, further solidifying the company's market position.
See More
InfuSystem Set to Announce Q4 Earnings Expectations
- Earnings Announcement Date: InfuSystem (INFU) is set to announce its Q4 earnings on February 24 before market open, with investors keenly awaiting its performance and future outlook.
- EPS Expectations: The consensus EPS estimate stands at $0.07, reflecting a substantial year-over-year increase of 75%, indicating a significant improvement in the company's profitability that could positively influence its stock price.
- Revenue Forecast: The anticipated revenue for Q4 is $36.68 million, representing an 8.4% year-over-year growth, which underscores the company's robust performance and ongoing customer demand in the market.
- Historical Performance Review: Over the past year, InfuSystem has beaten EPS estimates 25% of the time and revenue estimates 50% of the time, highlighting uncertainty in its financial forecasts, prompting investors to exercise caution in their evaluations.
See More
InfuSystem Schedules Q4 and FY 2025 Financial Results Conference Call
- Earnings Release Schedule: InfuSystem will issue its preliminary fourth quarter and full year 2025 financial results on February 24, 2026, before market open, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will hold a conference call at 9:00 a.m. Eastern Time on the same day to discuss its financial results with investors and stakeholders, aiming to bolster market confidence.
- Participation Method: Investors can join the call by dialing (833) 366-1127 or (412) 902-6773, or listen via a live webcast available on the company's website, reflecting the company's adaptation to modern communication methods.
- Replay Availability: A replay of the call will be accessible until March 3, 2026, allowing investors who cannot participate live to obtain the information, ensuring comprehensive communication with all stakeholders.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
InfuSystem Holdings Reports Strong Q4 2025 Earnings with Strategic Growth Outlook
- Significant Revenue Growth: InfuSystem reported net revenue of $36.2 million for Q4 2025, reflecting a 7% year-over-year increase, with Oncology and Wound Care segments growing by 2.8% and over 160% respectively, indicating strong performance in the medical device market.
- Record Adjusted EBITDA: The adjusted EBITDA for Q4 reached $8.8 million, representing 24.3% of net revenue, marking a quarterly record that highlights the company's success in cost control and operational efficiency.
- Optimistic Future Outlook: Management anticipates revenue growth between 6% and 8% for 2026, despite a $7.1 million revenue reduction due to contract restructuring, with new products and technology-driven efficiencies expected to support this growth.
- Robust Cash Flow: Operating cash flow for 2025 exceeded $24.4 million, with available liquidity nearing $58 million at year-end, demonstrating the company's ongoing commitment to capital allocation and shareholder value creation.
See More
InfuSystem Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: InfuSystem reported Q4 GAAP EPS of $0.10, beating expectations by $0.03, indicating robust profitability, while revenue reached $36.2 million, a 6.9% year-over-year increase, although it fell short of market expectations, reflecting intensified competition.
- Patient Services Growth: Patient Services net revenue was $21.9 million, up 5% year-over-year, indicating sustained growth in this segment, despite overall revenue not fully meeting market forecasts.
- Device Solutions Performance: Device Solutions net revenue reached $14.4 million, a 10% increase year-over-year, showcasing strong performance in equipment sales and further solidifying the company's market position.
- Future Outlook: The company anticipates a $7.1 million, or 5.5%, reduction in net revenue for 2026 due to biomedical services contract restructuring, but expects pro-forma net revenue growth for unaffected business to be between 6% and 8%, demonstrating confidence in future growth.
See More
InfuSystem Reports Record Revenues and Earnings for 2025
- Significant Revenue Growth: InfuSystem achieved net revenues of $143.4 million in 2025, a 6% increase year-over-year, marking the seventh consecutive year of record revenues, demonstrating the company's strong performance and growth potential in the healthcare equipment services market.
- Substantial Net Income Increase: The net income for 2025 reached $6.6 million, up 183% from the previous year, reflecting significant improvements in cost control and operational efficiency, which enhances investor confidence in future profitability.
- Record Adjusted EBITDA: The adjusted EBITDA for 2025 was $31.5 million, a 24% increase, indicating ongoing optimization in profitability and cash flow management, which supports future strategic investments and expansions.
- Robust Cash Flow: Operating cash flow for 2025 was $24.4 million, a 19% increase, providing ample liquidity to support business development and shareholder return plans, further solidifying the company's market position.
See More
InfuSystem Set to Announce Q4 Earnings Expectations
- Earnings Announcement Date: InfuSystem (INFU) is set to announce its Q4 earnings on February 24 before market open, with investors keenly awaiting its performance and future outlook.
- EPS Expectations: The consensus EPS estimate stands at $0.07, reflecting a substantial year-over-year increase of 75%, indicating a significant improvement in the company's profitability that could positively influence its stock price.
- Revenue Forecast: The anticipated revenue for Q4 is $36.68 million, representing an 8.4% year-over-year growth, which underscores the company's robust performance and ongoing customer demand in the market.
- Historical Performance Review: Over the past year, InfuSystem has beaten EPS estimates 25% of the time and revenue estimates 50% of the time, highlighting uncertainty in its financial forecasts, prompting investors to exercise caution in their evaluations.
See More
InfuSystem Schedules Q4 and FY 2025 Financial Results Conference Call
- Earnings Release Schedule: InfuSystem will issue its preliminary fourth quarter and full year 2025 financial results on February 24, 2026, before market open, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Timing: The company will hold a conference call at 9:00 a.m. Eastern Time on the same day to discuss its financial results with investors and stakeholders, aiming to bolster market confidence.
- Participation Method: Investors can join the call by dialing (833) 366-1127 or (412) 902-6773, or listen via a live webcast available on the company's website, reflecting the company's adaptation to modern communication methods.
- Replay Availability: A replay of the call will be accessible until March 3, 2026, allowing investors who cannot participate live to obtain the information, ensuring comprehensive communication with all stakeholders.
See More
IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%
- Strategic Alternatives: IO Biotech announced it will explore various strategic alternatives to maximize shareholder value, resulting in a 19.36% stock surge to $0.25, indicating strong investor interest in potential mergers or asset sales.
- Cost-Cutting Measures: The company is evaluating further reductions in force and other measures to significantly cut operating expenses, aiming to enhance financial flexibility and pave the way for future strategic options.
- Speculative Trading: Cue Biopharma's stock rose 10.67% to $0.42 despite no new company news, suggesting speculative trading activity may reflect investor optimism in the biotech sector.
- Continued Growth Trend: InfuSystem and Cabaletta Bio saw stock increases of 7.19% and 7.68%, respectively, demonstrating ongoing investor interest in the medical services and biotech sectors, despite the absence of new corporate updates.
See More
